Oruka (ORKA) Insider Sale of $687K Amid 700% Stock Surge

Arjun Agarwal, Senior Vice President of Oruka Therapeutics (ORKA), sold 9,854 shares for approximately $687,000 on June 12-15, 2026. The shares were sold at a weighted average price of $69.72 after experiencing a nearly 700% increase in stock value. Post-transaction, Agarwal's direct holdings decreased by 36.83%, from 26,753 to 16,899 shares. This transaction follows a notable surge in Oruka's stock driven by positive Phase 2 clinical data indicating 63.5% patient clearance with ORKA-001, creating heightened market interest.